STEP-HFpEF · 2023

STEP-HFpEF — Semaglutide in heart failure with preserved EF

Semaglutide in adults with obesity-related HFpEF.

Headline finding

Significant improvement in KCCQ-CSS and 6-minute walk distance.

Population
529 adults with HFpEF and obesity
Duration
52 weeks
Citation
Kosiborod MN et al., NEJM 2023

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation